Fresenius wins record low yield, but has to widen price on seven year
Sometimes it is difficult to live between two worlds. Fresenius, the Ba1/BB+ rated German healthcare business, is a speculative grade issuer, but prices so tight it could be investment grade.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
